Previous 10 | Next 10 |
Oppenheimer has downgraded Aurinia Pharmaceuticals (NASDAQ:AUPH) from outperform to perform following a report that the company may be acquired by Bristol-Myers Squibb (NYSE:BMY). In addition, the firm says that the current share price reflects appropriate valuation. Oppenheimer has a $32 pri...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that it will release its third quarter 2021 financial results on Wednesday, November 3, 2021, before the markets open. Aurinia’s management team will also host a conference call at 8:30 a.m....
Top Biotech Stocks To Consider Buying [Or Selling] This Week Depending on your investment appetite, the stock market offers various types of opportunities. Biotech stocks have a reputation for being a high-risk, high-reward kind of investment. Over the past two years, countless ...
Data to highlight the safety, tolerability and efficacy of LUPKYNIS in patients with lupus nephritis Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), a biopharma company committed to delivering therapeutics that change the course of autoimmune diseas...
Consumer-products giant Kimberly-Clark (NYSE:KMB) became the latest inflation victim on Monday. The maker of Kleenex and Cottonelle toilet paper dropped to a new 52-week low in midday trading on disappointing earnings results. Paysafe (NYSE:PSFE) also showed weakness in intraday action, falli...
Shares of Aurinia Pharmaceuticals (NASDAQ: AUPH) jumped by 26% during today's regular trading session. In Friday's after-hours session, however, the biotech's shares jumped by another 10.3% on exceedingly heavy volume. What's driving this sudden upward trend? A report from Blo...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the senior management team will present at the following upcoming virtual investor conferences: Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Monday, Sept...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the senior management team will participate in the H.C. Wainwright & Co. 23rd Annual Global Investment Conference, September 13-15, 2021. The Aurinia presentation will be av...
Could These Be The Top 4 Health Care Stocks To Watch Today? Health care stocks continue to take center stage in the stock market even as we face arduous challenges due to the global pandemic. Well, the health care industry and system are extremely important to every country and ...
Aurinia Pharmaceuticals has seen a nice surge in its stock price over the past month after reporting better-than-expected initial sales for its flagship product LUPKYNIS. Can the rally continue? We take a look at recent results, analyst commentary and other factors to attempt to ...
News, Short Squeeze, Breakout and More Instantly...
Aurinia Pharmaceuticals Inc Company Name:
AUPH Stock Symbol:
NASDAQ Market:
Aurinia Pharmaceuticals Inc Website:
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...
Company achieved $57.2 million in total net revenue and $55.0 million in net product revenue for the second quarter of 2024, representing year-over-year growth of approximately 38% and 34% respectively Company generated approximately $15.8 million in free cash flow in the second quarter a...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1, 2024, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30...